Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback